George-
Since this is a Cytopathology Convention, we should attempt to address issues related only to AccuMed's Cytopathology Division.
Is the TracCell 2000 slide mapping system (that received FDA clearance on August 18, '97) presently being marketed?
If "no" when (which quarter) is it expected to be?
Since the TracCell 2000 system is backward compatible with the (primary) AcCell, how many existing AcCell users are expected to
incorporate the TracCell 2000 into their existing modules?
Can you explain the "per slide use royalty fee" AccuMed is expecting to receive from the TracCell System? What revenues are expected annually from those royalty fees?
How far along in development is the AcCell Savant, and when will Oncometrics Imaging and AccuMed expect FDA approval of that system?
(Which quarter?) How large a market is that system looking to address?
How far along is the development of the AcCell System 3000, and will FDA approval also be required for that version? When will it become available for sale? What differentiates it from the competition?
The latest third quarter results (October 30, '97) states that there was "...a significant increase in contract proposals in the third quarter, the relatively long decision and budget cycles we are experiencing in most laboratories have impacted cytopathology sales. I am disappointed that we were not able to bring contract negotiations with several of the laboratories to completion in this quarter."
Question: What percent of those "significant" increases in contract "proposals" are expected to be consumated (signed) in this quarter?
Why should a potential lab consider AccuMed's cytopathology system
instead of NeoPath Inc, Cytyc Corp., or Neuromedical Systems, Inc.?
What are some of the discrete advantages to AccuMed's compared to the alternatives?
Have the International Cytopathologists/ Labs proclaimed a "De Facto" winner between the available competing cyto-imaging systems, or is it an open playing field?
If the FDA grants Primary Automatic Screening status to NeoPath Inc., how is that expected to impact the AcCell and TracCell product line?
Select the best and forget the rest.
Good luck and be forceful. You are a part owner of the company. Those people you will be talking to work for you.
Frank Buck |
